[Authors' response to the letter to the editor as regards the article "post-menopausal osteoporosis: primary prevention or excessive medication"].
Medicina de Familia y Comunitaria, Centro de Salud Aranbizkarra II, Vitoria-Gasteiz, Álava, España.
C
C
Mendoza-Edroso
Medicina de Familia y Comunitaria, Centro de Salud Aranbizkarra II, Vitoria-Gasteiz, Álava, España.
N
N
Sánchez Garrido-Lestache
Unidad de Investigación de Álava, Hospital Universitario Araba, Vitoria-Gasteiz, Álava, España.
A
A
López-Picado
D004164:Diphosphonates / Q000627:therapeutic use*; D004363:Drug Utilization / Q000706:statistics & numerical data*; D005260:Female; D006801:Humans; D009942:Organometallic Compounds / Q000627:therapeutic use*; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control*; D011322:Primary Prevention; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use*; D013876:Thiophenes / Q000627:therapeutic use*
D004164:Diphosphonates; D009942:Organometallic Compounds; D013876:Thiophenes; D020849:Raloxifene Hydrochloride